A scoping review of patient and public perspectives on cell and gene therapies-Reference-Cited by-同舟云学术

A scoping review of patient and public perspectives on cell and gene therapies

Published:2021-11 Issue:11 Volume:16 Page:1005-1017
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Macpherson Karen¹^ORCID,Aiyegbusi Olalekan Lee²³⁴^ORCID,Elston Lauren⁵,Myles Susan⁵,Washington Jennifer⁵,Sungum Nisha⁶,Briggs Mark⁷,Newsome Philip⁴⁶^ORCID,Calvert Melanie²³⁴⁸^ORCID

Affiliation:

1. Healthcare Improvement Scotland, Glasgow, G1 2NP, UK

2. Centre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK

3. National Institute for Health Research, Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, B15 2TT, UK

4. National Institute for Health Research (NIHR) Applied Research Centre West Midlands, University of Birmingham, Birmingham, B15 2TT, UK

5. Health Technology Wales, Cardiff, CF10 4PL, UK

6. University Hospital Birmingham NHS Foundation Trust, Birmingham, B15 2GW, UK

7. Velindre University NHS Trust, Nantgarw, Cardiff, CF15 7QZ, UK

8. National Institute for Health Research Surgical Reconstruction & Microbiology Research Centre, University of Birmingham, Birmingham, B15 2TT, UK

Abstract

Aim: The development and introduction of cell and gene therapies presents complex social and economic issues. Fully addressing these challenges requires engagement with patients and the public. Materials & methods: A systematically conducted scoping review was undertaken to gauge current patient and public knowledge and perspectives, and as such inform requirements for future research, education and engagement activities. Results: A heterogeneous collection of 35 studies were identified. Levels of knowledge among patients and the public were extremely variable. Studies indicated general acceptance of therapies. Conclusion: The review identified the need for tailored educational activities, and in particular the importance of addressing misconceptions. There is also a need for robust qualitative research considering perspectives on current and forthcoming licensed therapies.

Funder

Innovate UK

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2020-0181

Reference49 articles.

1. Regulation (EC) No 1394/2007 of the European parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) No 726/2004. European Parliment. Strasbourg, France. (2007).

2. Directive 2001/83/EC of the european parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. European Parliment. Strasbourg, France (2001).

3. Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis

4. Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

5. Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology